A Medscape review of women’s responses after orgasm puts a 117-participant study in context, without making continued activity an expectation.
On October 28, 2026, Medscape published a report examining whether women experience a refractory period after orgasm. The coverage centered on an exploratory study of 117 participants and brought together earlier research with commentary from sexologist Ana Lombardía.
The report focuses on a question that can get lost when sexual response is discussed mainly in terms of reaching orgasm: what happens afterward? For readers, the useful starting point is to separate the experience being described from expectations about what should happen next.
The study described in The Journal of Sexual Medicine was prospective and observational. It included 117 sexually active adult women in stable heterosexual relationships.
The investigators set out to examine whether women experience a post-orgasmic refractory period and what that experience might involve. The journal article describes the question as controversial, rather than treating the existence of a single female response pattern as settled.
The design matters because this was a study of reported sexual experiences, not a trial of an intervention. Understanding that purpose helps separate the research question from another question readers might bring to it: whether their own response needs to change.
Medscape reports that participants said they did not want to continue sexual activity after 94.2% of orgasmic encounters. The reported duration of that response ranged from 30 minutes to 21 hours.
A separate finding concerned encounters in which participants reached peak pleasure without orgasm. Medscape reports that 39.5% of those encounters involved a plateau of pleasure that intensified as activity continued.
These findings describe different circumstances. In the first, participants reported no wish to continue after orgasm. In the second, pleasure continued to build after a peak that did not include orgasm.
The distinction helps explain why the report is about more than whether women need a pause. It also concerns how pleasure and the wish to continue relate to the experience of orgasm. Those descriptions are as important as the percentages themselves.
For the main result, the denominator is encounters, not women. The 94.2% figure therefore does not mean that 94.2% of women experience a refractory period. The available abstract does not provide the total encounter count or the number of participants in each group, which limits assessment of the estimate’s precision.
The sample was also selected. According to the journal’s methods, women with menopausal symptoms or diagnosed sexual dysfunction were excluded. So were women with medical comorbidities or psychiatric illness, along with those taking medication that affected sexual function.
These exclusions matter particularly for midlife readers. The study should not be assumed to represent women navigating menopause or the health and medication circumstances left out of its sample. Its focus on stable heterosexual relationships also limits the range of relationship settings represented.
A wish to stop is not the same finding as physical inability to continue. Because the study was observational, it also cannot establish what caused the reported response. A biological mechanism would need evidence beyond a description of whether someone wanted more activity.
Lombardía suggested to Medscape that possible explanations for a pause include recovery or heightened clitoral sensitivity. Simply not wanting to continue was another possibility she raised. These are practitioner comments, not mechanisms established by this study.
There is also a publication-date discrepancy. Medscape says the study was published “last June,” while the journal page lists October 20, 2026. That inconsistency should remain visible rather than be resolved by assumption.
These are useful distinctions when assessing the quality of sexual-health advice online. A precise percentage needs a clear denominator, a defined population and an honest account of what was measured.
The earlier evidence described by Medscape gives this study a broader context: women’s responses after orgasm have been reported in different ways. It does not establish a single expected pattern.
In a 2021 exploratory internet-based survey, 419 women who identified as multiorgasmic were studied. Researchers identified four groups with different characteristics. Medscape presents this as evidence that even the category of multiple orgasm contains varied experiences.
That survey is useful as a contrast to the idea of one standard response. Because participants already identified as multiorgasmic, it does not estimate how all women respond after orgasm. It describes variation within a particular group.
The report also revisits hormone research. In a 2018 randomized, double-blind, placebo-controlled laboratory trial involving 27 women, intranasal oxytocin had no significant effect on the subjective or physiological measures assessed. Medscape notes that this finding does not rule out other roles for oxytocin.
A separate 2018 study found higher plasma oxytocin levels in women who experienced orgasm than in women with anorgasmia. However, its sample size and design did not support conclusions about causation. A difference in measured hormone levels is not proof that the hormone caused the response.
Medscape also describes a 2019 case report involving five cases of expanded sexual response, including prolonged or sustained orgasms in women around middle age. A 2026 laboratory case study involved one menopausal woman who induced orgasms without direct genital stimulation. The case series was very limited, and the single-participant finding cannot be generalized.
In this coverage, the survey illustrates differences within a self-selected group. The oxytocin trial tests a particular intervention. The case reports document individual experiences. None should be substituted for the encounter-level finding at the center of the new study.
Lombardía told Medscape that some women in her practice report needing to stop after orgasm for a while. She emphasized considerable variation in women’s responses. This is a clinical observation, not an estimate of how often women in general need a pause.
These reports sit alongside one another rather than forming a ladder of better and worse sexual responses. As Medscape emphasizes, the overall evidence remains limited and further research is needed. The new observational findings add to that discussion without settling it.
Lombardía’s clinical message in Medscape is that a pause should not automatically be treated as a condition requiring correction. She also cautions against making continued sexual activity or multiple orgasms an expectation.
For partners, that supports a simple approach to communication:
These are ways of respecting the person’s experience, not techniques for changing their sexual response. The study does not supply a reason to continue when someone wants to stop. The reported duration is descriptive, not a timetable that a partner should enforce.
Reading the findings this way also changes the question a partner might ask. Rather than asking why someone is not continuing, the conversation can focus on whether the experience is comfortable and wanted. There is no need to turn the answer into a comparison with other women or with a study percentage.
For an individual reader, curiosity and distress are different starting points. Someone who recognizes a familiar preference in the report may simply find language for it. Someone troubled by their experience may want to discuss the concern with a qualified clinician rather than adopt a label from a headline.
It can help to distinguish the questions involved: is the concern about wanting a pause, physical sensitivity or an experience that feels persistently troubling? That distinction does not diagnose anything. It keeps the discussion focused on the person’s experience instead of assuming that every pause has the same meaning.
Sexential’s context for changing desire in adulthood offers a broader educational perspective on sexual wellbeing. The point is not to make every part of intimacy fit a research category, but to make room for clear conversations about what someone actually wants.
A pause deserves respect, not a performance score.
A percentage about post-orgasmic pauses should not decide whether someone is expected to continue or stop. Sexential explains sexual function and intimacy for adults aged 35 to 65 through evidence-aware education that connects biology with real-life context rather than directing decisions about personal medical care.
Follow Sexential for thoughtful guidance on desire, sexual function, hormones, confidence, relationships and intimacy. Explore new articles and evidence-aware resources for sexual wellbeing across adulthood.
A large Epic Research review raises questions about repeat testing before testosterone prescriptions. Learn how the findings fit diagnostic guidance.
A 51-participant study linked estrogen plus testosterone to higher spine-density scores. See how the finding fits menopause guidance and sexual health.
A study found no significant total gray-matter decline in its menopause transition group. Read the finding, its limits and its relevance to midlife.
Explore practical resources on desire, function, hormones, confidence, intimacy and sexual wellbeing.
Read the Blog
